Effects of anacetrapib in patients with atherosclerotic vascular disease
<p>BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL chole...
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Publié: |
Massachusetts Medical Society
2017
|